Endo files U.S. application for product for cellulite treatment

Endo International plc (ENDP +9.7%) has submitted a marketing application to the FDA seeking approval to use collagenase clostridium histolyticum (CCH) to treat cellulite in the buttocks.

CCH, a combination of bacterial enzymes that break down collagen, is marketed in the U.S. by Endo’s pharmaceutical unit as XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease.

https://seekingalpha.com/news/3497671-endo-files-u-s-application-cch-cellulite-shares-10-percent